FUSION PROTEIN COMPRISING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF

Provided is a fusion protein dimer comprising: an extracellular domain of Complement receptor of the immunoglobulin superfamily (CRIg) or a fragment thereof; and a protein that specifically binds to vascular endothelial growth factor (VEGF). The protein can effectively regulate angiogenesis as well...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KIM DONGGEON, CHUNG EU DDEUM, RYU SOOMIN, CHANG JIHOON, LEE BYOUNG CHUL
Format:	Patent
Sprache:	eng ; kor
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Provided is a fusion protein dimer comprising: an extracellular domain of Complement receptor of the immunoglobulin superfamily (CRIg) or a fragment thereof; and a protein that specifically binds to vascular endothelial growth factor (VEGF). The protein can effectively regulate angiogenesis as well as inhibit complement-related pathways. Therefore, the fusion protein dimer can be effectively utilized for the treatment and prevention of complement-related diseases, in particular, eye diseases such as macular degeneration, and thus shows high industrial application potential. CRIg의 세포외도메인 또는 이의 단편 및 VEGF에 특이적으로 결합하는 단백질을 포함하는 융합단백질 이량체를 제공한다. 상기 단백질은 보체 관련 경로를 억제할 뿐 아니라 신생혈관생성을 효율적으로 조절할 수 있다. 따라서, 상기 융합단백질 이량체는 보체 관련 질환, 구체적으로 황반 변성과 같은 안질환의 치료 및 예방에 효과적으로 활용할 수 있어 산업적 활용 가능성이 높다.